AstraZeneca buying drug developer in £30bn deal

Astrazeneca Buying Drug Developer In £30Bn Deal Astrazeneca Buying Drug Developer In £30Bn Deal
AstraZenenca HQ, © AP/Press Association Images
Share this article

By Associated Press Reporter

Pharmaceutical giant AstraZeneca is to buy US drug developer Alexion in a deal worth almost £30 billion.

Cambridge-based AstraZeneca, which is developing a Covid-19 vaccine, said on Saturday it is using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals.

The boards of both companies have unanimously approved the transaction, but it still needs regulatory and shareholder approval.

AstraZeneca is currently developing a coronavirus vaccine with Oxford University (John Cairns/University of Oxford/PA)

The deal is expected to close in the third quarter of 2021.

AstraZeneca chief executive Pascal Soriot said: “This acquisition allows us to enhance our presence in immunology.”

The company and Oxford University have jointly developed a coronavirus vaccine that British and Canadian regulators are assessing.


Read More

Want us to email you top stories each lunch time?

Download our Apps
© 2023, developed by Square1 and powered by